血腺素和生物标志物确认的阿尔茨海默病在第三级记忆诊所的临床
Louise Sindzingre1,2, Elodie Bouaziz-Amar1,3, François Mouton-Liger1
1Université Paris Cité, UMRS 1144, INSERM, Paris, France.
Journal of neuroendocrinology
|January 22, 2025
概括
与对照组相比,阿尔茨海默病 (AD) 患者的血腺素水平较高. 然而,这种差异是由阿尔茨海默症组中年龄较大和女性性别等因素解释的.
科学领域:
- 神经科学是一个神经科学.
- 代谢研究的研究.
- 内分泌学 在内分泌学.
背景情况:
- 阿尔茨海默病 (AD) 与早期代谢功能障碍有关.
- 调节新陈代谢和炎症的激素阿迪波内克可能在AD病理生理学中发挥作用.
- 以前的研究表明,阿迪波涅克丁和AD之间存在联系.
研究的目的:
- 为了研究AD患者和神经学对照者之间血阿迪波内克水平的差异.
- 分析阿迪波涅克丁水平与阿尔茨海默病之间的关系,考虑到人口和代谢因素.
主要方法:
- 追溯,横截面的观察性研究,涉及142名阿尔茨海默病患者和64名对照.
- 用化学发光酶免疫试验测量血腺素水平.
- 用于分析关联的线性回归模型,根据年龄,性别和BMI进行调整.
主要成果:
- 亚当氏病患者的血腺素水平明显高 (6.45微克/毫升) 比对照组 (4.85微克/毫升).
- 在女性和老年人中观察到较高的阿迪波涅丁度.
- 阿迪波涅克丁和AD之间的关联是由年龄,性别和BMI调解的;在多变量模型中,阿迪波涅克丁与AD没有独立相关.
结论:
- 虽然阿尔茨海默病患者的血腺素水平较高,但这种关联是由人口因素 (年龄较大,女性性别) 和阿尔茨海默病组内较低的BMI驱动的.
- 需要进一步的研究,才能充分了解阿尔茨海默病中的荷尔蒙特征.
相关概念视频
Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160


